New data from an extension period of a phase 3 study of Samsung Bioepis’ SB2 (Renflexis) in patients with moderate to severe rheumatoid arthritis found that there was no clinically meaningful difference in safety, efficacy, or immunogenicity in patients who were switched from reference infliximab to the biosimilar compared with patients who continued treatment with either the reference or the biosimilar without switching.
New data from an extension period of a phase 3 study of Samsung Bioepis’ SB2 (Renflexis) in patients with moderate to severe rheumatoid arthritis (RA) found that there was no clinically meaningful difference in safety, efficacy, or immunogenicity in patients who were switched from reference infliximab to the biosimilar compared with patients who continued treatment with either the reference or the biosimilar without switching. Additionally, patients who received the biosimilar alone, and were not switched, maintained long-term efficacy, safety, and immunogenicity that was comparable with patients who received the reference product alone.
The new data present clinical efficacy and safety results of SB2 in patients with RA for up to 78 weeks (previous reports were up to week 54). The objective of this extension was to investigate whether patients being treated for RA with reference infliximab could be switched to SB2 without major concerns, and whether comparable efficacy, safety, and immunogenicity were maintained after the switch (compared with continued treatment with either reference infliximab or SB2 only).
Patients with RA who had participated in the original 54-week, double-blind period and who were willing to participate in the extension (n = 396) were randomized to either transition to SB2 from reference infliximab (n = 94) or to continue treatment with reference infliximab (n = 101) or SB2 (n = 201), up to week 70. The final follow-up occurred at week 78.
Treatment efficacy among the 3 arms was comparable at week 78 in terms of the American College of Rheumatology (ACR) responses of 20%, 50%, and 70% improvement:
The percentage of patients achieving good European League Against Rheumatism (EULAR) responses at week 78 were as follows:
The percentage of patients in each arm who developed new ADAs to their assigned treatment were as follows:
The study’s authors concluded that the clinical profile of SB2, administered either in the long term or when switched from the reference infliximab, is comparable with that of the reference. “Our data showing that switching from originator to biosimilar is safe and effective are corroborated by the recent observations in the NOR-SWITCH and DANBIO [studies],” said the authors.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.